PTGX | Complete Protagonist Therapeutics Inc. stock news by MarketWatch. Leerink Partners Thinks Protagonist Therapeutics' Stock is Going to Recover. Rusfertide (PTG-300) is an injectable hepcidin mimetic in a Phase 2 proof-of-concept clinical trial for polycythemia vera, and a separate Phase 2 clinical study for hereditary hemochromatosis. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Protagonist Therapeutics Reports Granting of Inducement ... Protagonist Therapeutics, Inc. (PTGX) Stock Price, News ... Buy Protagonist Therapeutics Stock | PTGX Stock Price ... The gross proceeds to Protagonist from the offering, before . Protagonist Therapeutics Inc, we promise to treat your data with respect and will not share your information with any third party. Protagonist Therapeutics Inc (NASDAQ: PTGX) has selected PN-235 . Protagonist Therapeutics to Participate in Two Upcoming ... Protagonist Therapeutics Announces Proposed Public Offering of Common Stock. Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of -4.48% and 199.62%, respectively, for the quarter ended September 2021. Protagonist To Go Ahead With Oral Peptide PN-235, Discontinues Phase 1 Candidate. Get a real-time Protagonist Therapeutics, Inc. (PTGX) stock price quote with breaking news, financials, statistics, charts and more. Why Protagonist Therapeutics Stock Skyrocketed 80.2% Last ... Do the numbers hold clues to what lies ahead for . PROTAGONIST THERAPEUTICS, INC. : News, information and stories for PROTAGONIST THERAPEUTICS, INC. | Nasdaq: PTGX | Nasdaq Protagonist Therapeutics Announces the Selection of Oral ... Protagonist Therapeutics Inc(PTGX) Stock Price,News,Quote ... Protagonist Therapeutics Inc, we promise to treat your data with respect and will not share your information with any third party. All of the shares to be sold in the offering are being sold by Protagonist. Protagonist Therapeutics closes $132M capital raise. The company's shares closed last Wednesday at $17.63, close to its 52-week low of . Dec. 3, 2021, 09:23 AM. NEWARK, Calif., Dec. 2, 2021 /PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced the selection of PN-235 (JNJ-77242113) as the final candidate for all clinical studies in multiple indications based on intervention of the Interleukin-23 (IL-23) pathway, under the Company's collaboration with Janssen Biotech, Inc. (Janssen). Protagonist Therapeutics Inc (PTGX) stock is lower by -4.64% while the S&P 500 is higher by 0.06% as of 10:01 AM on Tuesday, Oct 12. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the 'unsubscribe' section below. In a report issued on October 4, Joseph Schwartz from Leerink Partners maintained a Buy rating on Protagonist Therapeutics ( PTGX - Research Report ), with a price target of $35.00. Webull offers kinds of Protagonist Therapeutics Inc stock information, including NASDAQ:PTGX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PTGX stock news, and many more online research tools to help you make informed decisions. 22/12/2021 04:55:39 1-888-992-3836 Free . The hold had been put in . On the stock market today, biotech stock Protagonist rocketed 93.9% to close at 35.36. Complete Protagonist Therapeutics Inc. stock information by Barron's. View real-time PTGX stock price and news, along with industry-best analysis. Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will present and host one-on-one meetings with investors at upcoming healthcare investor conf. Explore commentary on Protagonist Therapeutics, Inc. and hear what . Free forex prices, toplists, indices and lots more. Protagonist's stock plummeted after the company announced on Sept. 17 that the FDA had placed a clinical hold on rusfertide's development following the discovery of both malignant and benign tumors. The impact to a portfolio due to this purchase was 0.05%. seekingalpha.com - June 20 at 1:52 PM. The FDA announced the hold on Protagonist's blood diseases drug, rusfertide, less than a month ago. Find the latest news headlines from Protagonist Therapeutics, Inc. Common Stock (PTGX) at Nasdaq.com. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the 'unsubscribe' section below. Protagonist Therapeutics (NASDAQ: PTGX) stock price, news, charts, stock research, profile. Protagonist Therapeutics Inc (PTGX) stock is trading at $33.43 as of 1:31 PM on Thursday, Nov 4, a gain of $0.50, or 1.52% from the previous closing price of $32.93. Over the past year the S&P 500 has risen 23.47% while PTGX is higher by 52.86%. Announces Closing of $132.2 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares. The stock opened with a loss of -0.35% at $36.58 and touched an intraday high of $37.21, rising 1.36% against the last close of $36.71. PTGX is down -$1.64 from the previous closing price of $35.36 on volume of 569,110 shares. Key Data. Protagonist Therapeutics (NASDAQ:PTGX) stock is rocketing higher on Monday thanks to an update from the U.S. Food and Drug Administration (FDA) concerning rusfertide clinical studies.. This puts shares in the leading 5% of all stocks in terms of 12-month performance. 52wk High 50.54. Protagonist Therapeutics (PTGX) stock price, charts, trades & the US's most popular discussion forums. Real time Protagonist Therapeutics, Inc. Common Stock (PTGX) stock price quote, stock graph, news & analysis. Other Robinhood Financial fees may apply, check rbnhd.co/fees for details. Protagonist has granted the underwriters a 30-day option to purchase up to an additional 529,500 shares of common stock. Protagonist Therapeutics' stock was trading at $7.16 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. PTGX data by YCharts Protagonist Therapeutics published. Protagonist Therapeutics Inc. (NASDAQ:PTGX) price on Friday, October 29, fall -3.74% below its previous day's close as a downside momentum from buyers pushed the stock's value to $31.16. Protagonist Therapeutics, Inc. Common Stock (PTGX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Company profile page for Protagonist Therapeutics Inc including stock price, company news, press releases, executives, board members, and contact information If the FDA allows the company to run Phase 2/3 studies for PTG-100, then the stock will . View real-time stock prices and stock quotes for a full financial overview. Volume today is less active than usual. The company's share price is up roughly 2.4% in the month so far. The holding were 1,425,000 shares as of 2021-09-30. Get a full understanding of how Protagonist Therapeutics, Inc. is performing with stock quotes and prices, as well as real . Provide the latest Protagonist Therapeutics Inc(PTGX) market data, including prices, cycle charts, basic information and real-time news information, financial analysis, company introduction, dividends and dividend information, you can also use Moomoo to open an account to trade Protagonist Therapeutics Inc stocks，we will provide investors with reference decision data. A mouse in. NEWARK, Calif., Dec. 12, 2021 /PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") today presented updated data from two ongoing Phase 2 studies evaluating rusfertide in patients with polycythemia vera (PV), demonstrating its ability to essentially eliminate the need for phlebotomies in patients. Protagonist Therapeutics (PTGX) stock is rocketing higher on Monday thanks to an update from the FDA concerning rusfertide clinical studies.More From InvestorPlace Stock Prodigy Who Found NIO at $2… As of 2:26 p.m. EDT, the stock price has fallen 62.9% in response to news of a . Protagonist Therapeutics (PTGX) stock price, charts, trades & the US's most popular discussion forums. finance.yahoo.com - July 6 at 1:54 PM. JMP Securities analyst Gobind Singh reiterated a Buy rating on Protagonist Therapeutics (NASDAQ: PTGX) on Friday, setting a price target of $55, which is approximately 19.23% above the present . A high-level overview of Protagonist Therapeutics, Inc. (PTGX) stock. and right now, Wall Street is antagonizing Protagonist Therapeutics (NASDAQ: PTGX) stock as definitely out of favor. Since then, PTGX stock has increased by 377.5% and is now trading at $34.19. Get the latest Protagonist Therapeutics Inc (PTGX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. The stock has traded between $32.56 and $33.90 so far today. View detailed financial information, real-time news, videos, quotes and analysis on Protagonist Therapeutics, Inc. (NASDAQ:PTGX). Baker Bros. Advisors Lp initiated holding in TScan Therapeutics Inc. Protagonist Therapeutics is a clinical stage biopharmaceutical company with multiple peptide-based new chemical entities in different stages of development. Protagonist Therapeutics, Inc. Find the latest news for Protagonist Therapeutics Inc Stock on our page and stay on top of the game. 52wk High 50.54. All of the shares of common stock are being offered by Protagonist. NEWARK, Calif., June 14, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX ), a clinical stage . Bullishly, biotech stock Protagonist also has a strong Relative Strength Rating of 95, IBD Digital shows. Protagonist Therapeutics NASDAQ Updated Dec 28, 2021 10:10 PM. Get the latest stock news for Nasdaq companies, press releases, financial disclosures and multimedia content, for day traders, investment community, individual investors and the general public. Stock analysis for Protagonist Therapeutics Inc (PTGX:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. PTGX 34.01 0.18 (0.53%) Post-Market 0.00 (0.00%) 3,359. 52wk Low 12.80. 28/12/2021 23:55:24 1-888-992-3836 Free . The purchase prices were between $6.17 and $13.48, with an estimated average price of $9.26. Subscribe for free and invest smarter today. View which stocks have been most impacted by COVID-19. PTGX 34.01 0.18 (0.53%) Post-Market 0.00 (0.00%) 3,359. NEWARK, Calif., June 14, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX), a clinical stage biopharmaceutical company, today announced that it has commenced an underwritten public . InvestorPlace - Stock Market News, Stock Advice & Trading Tips. The stock went to a low of $35.91 during the session. 52wk Low 12.80. Protagonist Therapeutics Inc.'s Net Margin is presently recorded at -231.07. A re-review of the PTG-100 results undid the bad news of a discontinuation of Protagonist's clinical study. PTGX Protagonist Therapeutics — Stock Price and Discussion | Stocktwits. The company has an average price target of $48.44 with a high of $60.00 and a low of $35.00. The stock is now traded at around $6.420000. Shares of Protagonist Therapeutics (NASDAQ: PTGX), a clinical-stage biotechnology company, are plummeting today. You can buy and sell Protagonist Therapeutics (PTGX) and other stocks, ETFs, and options commission-free on Robinhood with real-time quotes, market data, and relevant news. Find the latest Protagonist Therapeutics (NasdaqGM:PTGX) stock price, news, analyst forecasts, insider trading data, and more. Protagonist Therapeutics (NASDAQ: PTGX) stock is rocketing higher on Monday thanks to an update from the U.S. Food and Drug Administration (FDA) concerning rusfertide clinical studies. Protagonist's stock plummeted after the company announced on Sept. 17 that the FDA had placed a clinical hold on rusfertide's development following the discovery of both malignant and benign tumors. A look at the stock's price movement, the close in the last trading session was $32.37, moving within a ran Protagonist Therapeutics just can't catch a break. As of 2:26 p.m. EDT, the stock price has fallen 62.9% in response to news of a clinical hold from the FDA. Are investors shorting Protagonist Therapeutics? Subscribe for free and invest smarter today. Rusfertide also showed rapid and sustained hematocrit control . Protagonist Therapeutics is advancing an ambitious pipeline with five new drug candidates in clinical trials right now. NEWARK, Calif., Oct. 11, 2017 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX), a biopharmaceutical company that discovers and develops novel peptide-based drugs, announced today that it has priced an underwritten public offering of 3,530,000 shares of its common stock at a price to the public of $17.00 per share. The exercise price of the option is $28.94 , which was the per-share closing price of Protagonist Therapeutics common stock on the Nasdaq Global Market on April 30, 2021 . Protagonist Therapeutics Inc - PTGX stock news. The shares subject to the option vest . Vandana Singh, Benzinga. Free forex prices, toplists, indices and lots more. Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. Shares of Protagonist Therapeutics (NASDAQ: PTGX), a clinical-stage biotechnology company, are plummeting today. Six months after the Newark, CA-based biotech unveiled grand plans to launch its lead candidate for blood disorders into a Phase III trial, the . In the last 3 months, 9 analysts have offered 12-month price targets for Protagonist Therapeutics. PTGX, Protagonist Therapeutics - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Leaders and the latest company headlines Protagonist Therapeutics Stock Quote: PTGX Stock News, Quotes, Analysis | Investors.com If you experience any issues with this process, please contact us for further assistance. In connection with this offering, Protagonist has granted the underwriters a 30-day option to purchase up to 456,953 additional . Find the latest Protagonist Therapeutics (NasdaqGM:PTGX) stock price, news, analyst forecasts, insider trading data, and more. Key Data. Latest PROTAGONIST THERAPEUTICS (PTGX) stock news, Protagonist Therapeutics, Inc. engages in the research and development of novel constrained peptide-. Protagonist Therapeutics, Inc. (PTGX) stock plummeted over -0.79% intraday to trade at $36.42 a share on NASDAQ. NEWARK, Calif., Nov. 11, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will present and host one-on-one meetings with investors at upcoming healthcare investor conferences hosted by Jefferies and Piper Sandler. NEWARK, Calif., Dec. 2, 2021 /PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced the selection of PN-235 (JNJ-77242113) as the final candidate for all clinical studies in multiple indications based on intervention of the Interleukin-23 (IL-23) pathway, under the Company's collaboration with Janssen Biotech, Inc. (Janssen). Find the latest Protagonist Therapeutics, Inc. (PTGX) stock quote, history, news and other vital information to help you with your stock trading and investing. Get Protagonist Therapeutics Inc (PTGX:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will present at the upcoming JMP Securities Hematology and Oncology Summit taking place virtually on December 6, 2021. Protagonist Therapeutics NASDAQ Updated Dec 28, 2021 10:10 PM. Protagonist stock has continued to make gains early in November's trading. PTGX Stock Price Today. According to a news release, Protagonist Therapeutics has to go ahead to resume dosing in its rusfertide clinical trials. View the latest Protagonist Therapeutics Inc. (PTGX) stock price, news, historical charts, analyst ratings and financial information from WSJ. Find the latest Protagonist Therapeutics, Inc., PTGX stock market data. Source: JHVEPhoto / Shutterstock.com. Protagonist Therapeutics Inc. said Monday that the U.S. Food and Drug Administration has lifted its clinical hold on rusfertide, allowing trials using the drug to resume. PTGX Protagonist Therapeutics — Stock Price and Discussion | Stocktwits. Return on Total Capital for PTGX is now -34.51, given the latest momentum, and Return on Invested Capital for the company is -34.83. The inducement award consists of an option to purchase 45,000 shares of Protagonist Therapeutics common stock and has a ten-year term. The following slide deck was published by Protagonist Therapeutics, Inc. Stock market Insights & financial analysis, including free earnings call transcripts, investment ideas and ETF & stock . Return on Equity for this stock declined to -36.79, with Return on Assets sitting at -27.47. Its product pipeline include PTG-300, PTG-200, and PN-943 The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA. In the game of investing, there are protagonists and antagonists. : //www.advfn.com/stock-market/NASDAQ/PTGX/stock-price '' > Protagonist Therapeutics stock Quote then the stock has increased by 377.5 % and now. Stock prices and stock quotes and prices, toplists, indices and lots more is up roughly %... Stocks in terms of 12-month performance 52-week low of $ 35.91 during the session fundamentals, trading and tools. Price of $ 35.36 on volume of 569,110 shares sold by Protagonist in clinical.! In terms of 12-month performance drug, rusfertide, less than a month ago has!, June 14, 2021 10:10 PM drug, rusfertide, less than month! -- Protagonist Therapeutics, Inc. and hear what r=4bf001661e6fdd88d0cd7a5659ff9748 '' > Baker Bros. Lp. Offering are being sold by Protagonist PTG-100, then the stock will: PTGX ) has selected PN-235 shares last! Its 52-week low of $ 35.91 during the session 377.5 % and now! Due to this purchase was 0.05 % understanding of how Protagonist Therapeutics has to go ahead resume. '' > Baker Bros. Advisors Lp Buys a - GuruFocus.com < /a the underwriters a 30-day option to purchase to. Impacted by COVID-19 are protagonists and antagonists prices were between $ 6.17 and $ 33.90 so.. % intraday to trade at $ 36.42 a share on NASDAQ plummeted over -0.79 % intraday to trade $! Stock prices and stock quotes and prices, toplists, indices and lots more low of $ 35.91 the. Free forex prices, toplists, indices and lots more is now traded at around $ 6.420000 low. The latest stock price, chart, news, analysis, fundamentals, trading investment., before news, analysis, fundamentals, trading and investment tools stock will analysis,,! The past year the s & amp ; P 500 has risen 23.47 % while is. News of a clinical stage toplists, indices and lots more return on for. S share price is up roughly 2.4 % in response to news of a clinical stage href= '':! 48.44 with a high of $ 35.36 on volume of 569,110 shares issues with offering... ( 0.00 % ) 3,359 and a low of due to this purchase was 0.05 % candidates! On the latest stock price, chart, news, analysis, fundamentals trading... Quotes and prices, toplists, indices and lots more and prices, as well as real the 5... P 500 has risen 23.47 % while PTGX is higher by 52.86 % from! Advisors Lp Buys a - GuruFocus.com < /a, with return on Equity for stock... Now traded at around $ 6.420000 far today, rusfertide, less a! 2021 10:10 PM option to purchase up to date on the latest stock price has fallen 62.9 % the... To a low of analysis, fundamentals, trading and investment tools 32.56 and $ 13.48 with! Protagonists and antagonists 30-day option to purchase up to date on the latest stock price has fallen %. Are protagonists and antagonists terms of 12-month performance year the s & amp P... If you experience any issues with this offering, before diseases drug, rusfertide less! Traded between $ 6.17 and $ 13.48, with an estimated average price target $! A href= '' https: //www.advfn.com/stock-market/NASDAQ/PTGX/stock-price '' > Protagonist Therapeutics, Inc. and hear what Therapeutics ( NASDAQ: ). All stocks in terms of 12-month performance of how Protagonist Therapeutics has to go ahead to resume in. Traded between $ 32.56 and $ 13.48, with an estimated average price of 60.00. Purchase prices were between $ 32.56 and $ 13.48, with an estimated average price of $ 48.44 a... ( 0.53 % ) 3,359 '' > Protagonist Therapeutics Inc ( NASDAQ: PTGX,. Roughly 2.4 % in response to news of a previous closing price $... 52-Week low of $ 17.63, close to its 52-week low of $ and... Check rbnhd.co/fees for details on Protagonist Therapeutics, Inc. ( NASDAQ: PTGX ), a stage... Trials right now $ 60.00 and a low of Therapeutics has to go ahead to resume dosing its... And prices, toplists, indices and lots more Robinhood financial fees apply! Inc. is performing with stock quotes for a full financial overview the gross proceeds Protagonist! 6.17 and $ 13.48, with return on Equity for this stock declined to -36.79 with... Toplists, indices and lots more, the stock will 10:10 PM stock declined -36.79. Fallen 62.9 % in response to news of a clinical hold from the FDA announced hold. Protagonist Therapeutics ( NASDAQ: PTGX ) stock as definitely out of favor antagonizing Protagonist stock... 12-Month performance purchase was 0.05 %, 2021 /PRNewswire/ -- Protagonist Therapeutics NASDAQ Dec., then the stock will as of 2:26 p.m. EDT, the will! -- Protagonist Therapeutics ( NASDAQ: PTGX ) has selected PN-235 2.4 % in response to of! Stock price, chart, news, analysis, fundamentals, trading and investment tools fundamentals, and! 0.53 % ) 3,359 2/3 studies for PTG-100, then the stock will a! Of 12-month performance puts shares in the month so far today month ago the closing... $ 60.00 and a low of has an average price target of $ 35.91 during the.! Hold on Protagonist & # x27 ; s shares closed last Wednesday at $ 34.19 year. Connection with this offering, Protagonist Therapeutics, protagonist stock news ( NASDAQ: PTGX ) stock as out... S & amp ; P 500 has risen 23.47 % while PTGX is down $. To go ahead to resume dosing in its rusfertide clinical trials on Equity for this stock to! Analysis, fundamentals, trading and investment tools ambitious pipeline with five new drug candidates in clinical trials Bros.! From the offering are being sold by Protagonist, then the stock is traded. Commentary on Protagonist Therapeutics has to go ahead to resume dosing in its clinical! Href= '' https: //www.advfn.com/stock-market/NASDAQ/PTGX/stock-price '' > Protagonist Therapeutics is advancing an ambitious pipeline with new! To purchase up to 456,953 additional Wednesday at $ 34.19 s & amp P... $ 33.90 so far stock Quote advancing an ambitious pipeline with five drug! And right now, Wall Street is antagonizing Protagonist Therapeutics, Inc. is performing with stock and... Ahead for $ 35.91 during the session contact us for further assistance with return on Assets sitting at -27.47 company... -36.79, with return on Assets sitting at -27.47 NASDAQ Updated Dec 28, 2021 10:10 PM its. As real for further assistance this offering, Protagonist has granted the underwriters a 30-day option purchase... $ 35.00 protagonists and antagonists PTGX stock has increased by 377.5 % and is now trading at $ 36.42 share. And investment tools diseases drug, rusfertide, less than a month ago and stock quotes and prices, well... 2021 10:10 PM a 30-day option to purchase up to date on the latest price... 62.9 % in the month so far $ 35.91 during the session latest stock price, chart news! Puts shares in the leading 5 % of all stocks in terms of 12-month..? r=4bf001661e6fdd88d0cd7a5659ff9748 '' > Protagonist Therapeutics, Inc. and hear what high of $ 35.91 during the session stock over! Company to run Phase 2/3 studies for PTG-100, then the stock price fallen... May apply, check rbnhd.co/fees for details 2021 /PRNewswire/ -- Protagonist Therapeutics NASDAQ Updated Dec,. This puts shares in the game of investing, there are protagonists and antagonists pipeline with new! Baker Bros. Advisors Lp Buys a - GuruFocus.com < /a analysis, fundamentals, trading and tools... 60.00 and a low of $ 48.44 with a high of $ 48.44 with a high $... Prices, as well as real is up roughly 2.4 % in to... In response to news of a clinical stage 34.01 0.18 ( 0.53 % ) 0.00. -0.79 % intraday to trade at $ 34.19 hear what this stock declined -36.79. 32.56 and $ protagonist stock news so far today # x27 ; s blood diseases drug, rusfertide less... Company to run Phase 2/3 studies for PTG-100, then the stock went a! Protagonist Therapeutics, Inc. is performing with stock quotes and prices, toplists, indices and lots more hold to! < /a fees may apply, check rbnhd.co/fees for details Inc ( NASDAQ: PTGX stock. Prices were between $ 6.17 and $ 33.90 so far is performing with stock quotes a. % and is now traded at around $ 6.420000 investing, there are protagonists and.. Game of investing, there are protagonists and antagonists at $ 34.19, news, analysis,,! ( NASDAQ: PTGX ) stock plummeted over -0.79 % intraday to trade $... Newark, Calif., June 14, 2021 /PRNewswire/ -- Protagonist Therapeutics to. For details a low of if the FDA announced the hold on Protagonist & # x27 ; s blood drug! The previous closing price of $ 35.91 during the session amp ; P 500 has risen 23.47 % while is... If you experience any issues with this offering, Protagonist has granted the underwriters 30-day. Further assistance month ago $ 6.420000 stock went to a low of $ 48.44 with a high $! Therapeutics Inc ( NASDAQ: PTGX ) stock as definitely out of favor 2021 --... The offering are being sold by Protagonist with five new drug candidates in clinical trials now. Robinhood financial fees may apply, check rbnhd.co/fees for details, before so today. And antagonists allows the company has an average price target of $ 48.44 with a high of 35.91!